Proteasome inhibitors in the treatment of B-cell malignancies

Clinical Lymphoma

Volumn 3, Issue 1, 2002, Pages 49-55

  Schenkein, David ^a  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

Bortezomib; I B; Multiple myeloma; Non Hodgkin's lymphoma; Nuclear factor B; Peripheral neuropathy; Ubiquitin proteasome pathway

Indexed keywords

ANTINEOPLASTIC AGENT; APC PROTEIN; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORONIC ACID DERIVATIVE; BORTEZOMIB; CALPASTATIN; CYCLIN DEPENDENT KINASE; CYCLINE; DEXAMETHASONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KI 67 ANTIGEN; LACTACYSTIN; MYC PROTEIN; PLATINUM DERIVATIVE; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN C FOS; PROTEIN P130; PROTEIN P53; PROTEIN TYROSINE PHOSPHATASE; TAXANE DERIVATIVE; TRANSCRIPTION FACTOR; TYROSINE AMINOTRANSFERASE; UBIQUITIN; ACETYLCYSTEINE; ATP DEPENDENT 26S PROTEASE; BENZYLOXYCARBONYLLEUCYL LEUCYL LEUCINE ALDEHYDE; BENZYLOXYCARBONYLLEUCYL-LEUCYL-LEUCINE ALDEHYDE; CELL CYCLE PROTEIN; DRUG DERIVATIVE; ENZYME; LEUPEPTIN; ONCOPROTEIN; PEPTIDE HYDROLASE; PROTEINASE INHIBITOR; PYRAZINE DERIVATIVE; TUMOR PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CELL CYCLE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; ENZYME INHIBITION; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; MANTLE CELL LYMPHOMA; MOUSE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; ONCOGENE C MYC; PROTEIN STABILITY; REGULATORY MECHANISM; SIDE EFFECT; ANIMAL; B CELL LEUKEMIA; DRUG ANTAGONISM; DRUG SCREENING; ENZYME SPECIFICITY; ENZYMOLOGY; GENE EXPRESSION REGULATION; METABOLISM; PHYSIOLOGY; REVIEW; TREATMENT OUTCOME; ULTRASTRUCTURE;

ACETYLCYSTEINE; ANIMALS; BORONIC ACIDS; CELL CYCLE PROTEINS; CLINICAL TRIALS; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYMES; GENE EXPRESSION REGULATION; HODGKIN DISEASE; HUMANS; LEUKEMIA, B-CELL; LEUPEPTINS; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; LYMPHOMA, MANTLE-CELL; MICE; MULTIPLE MYELOMA; NEOPLASM PROTEINS; NF-KAPPA B; ONCOGENE PROTEINS; PEPTIDE HYDROLASES; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; SUBSTRATE SPECIFICITY; TRANSCRIPTION FACTORS; TREATMENT OUTCOME;

EID: 0036348365     PISSN: 15269655     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2002.n.011     Document Type: Article

References (68)

1. Proteasome inhibitors: A novel class of potent and effective antitumor agents
2. Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome
3. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: Implications for systemic nuclear factor-kappaB inhibition
4. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells
5. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer
6. Dose-dependent inhibition of 20S proteasome results in serum IL-6 and PSA decline in patients (pts) with androgen-independent prostate cancer (AI PCa) treated with the proteasome inhibitor PS-341
7. A phase I trial of the novel proteasome inhibitor PS-341 in advanced solid tumor malignancies
8. Structure of 20S proteasome from yeast at 2.4 Å resolution
9. Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 Å resolution
10. Catalytic mechanism of the 20S proteasome of thermoplasma acidophilum revealed by x-ray crystallography
11. Why does threonine, and not serine, function as the active site nucleophile in proteasomes?
12. Cleavage motifs of the yeast 20S proteasome β subunits deduced from digests of enolase 1
13. Protease inhibitor-induced apoptosis: Accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition
14. Inhibition of nuclear factor κB activation attenuates apoptosis resistance in lymphoid cells
15. The proteasome controls the expression of a proliferation-associated nuclear antigen Ki-67
16. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27
17. p53-dependent cell cycle arrest induced by N-acetyl-L-leucinyl-L-leucinyl-L-norleucinal in platelet-derived growth factor-stimulated human fibroblasts
18. Phosphorylation and proteasome dependent degradation of Bcl-2 in mitotic-arrested cells after microtubule damage
19. Activation of NF-κB requires proteolysis of the inhibitor IκB-α: Signal-induced phosphorylation of IκB-a alone does not release active NF-κB
20. Role of IκBa ubiquitination in signal-induced activation of NF-κB in vivo
21. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest
22. How proteolysis drives the cell cycle
23. Increased sensitivity of CLL-derived lymphocytes to apoptotic death activation by the proteasome-specific inhibitor lactacystin
24. Proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma cells to chemotherapeutic agents and overcomes chemoresistance through inhibition of the NF-κB pathway
25. Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor
26. Activation of the cell death program by inhibition of proteasome function
27. Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased over-all survival in mantle cell lymphoma
28. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts
29. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB
30. Signal-induced degradation of IκBα requires site-specific ubiquitination
31. Signal-induced ubiquitination of IκBα by the F-box protein Slimb/β-TrCP
32. The SCFβ-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IκBα and b-catenin and stimulates IκBα ubiquitination in vitro
33. Stimulation-dependent IkBa phosphorylation marks the NF-kB inhibitor for degradation via the ubiquitin-proteasome pathway
34. Critical role for lysines 21 and 22 in signal-induced, ubiquitin-mediated proteolysis of IκBα
35. Signal-induced site-specific phosphorylation targets IkBa to the ubiquitin-proteasome pathway
36. The Rel/NF-κB family directly activates expression of the apoptosis inhibitor Bcl-x(L)
37. NF-kB antiapoptosis: Induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation
38. NF-κB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis
39. The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-κB that blocks TNFa-induced apoptosis
40. Mutual regulation of the transcriptional activator NF-κB and its inhibitor, IκBα
41. Transcription factor NF-κB is constitutively activated in acute lymphoblastic leukemia cells
42. New insights into role of microenvironment in multiple myeloma
43. Analysis of expression of nuclear factor kappa B (NF-kappa B) in multiple myeloma: Downregulation of NF-kappa B induces apoptosis
44. Paclitaxel sensitivity of breast cancer cells with constitutively active NF-κB is enhanced by IκBα super-repressor and parthenolide
45. NF-κB in cancer: From innocent bystander to major culprit
46. The role of nuclear factor-κB in the biology and treatment of multiple myeloma
47. NF-κB and chemoresistance: Potentiation of cancer drugs via inhibition of NF-κB
48. The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo-and radioresistant human chronic lymphocytic leukemia lymphocytes to TNF-α-initiated apoptosis
49. Protease inhibitors restore radiation-induced apoptosis to Bcl-2-expressing lymphoma cells
50. Essentials of molecular biology: Basic principles
51. Characterization of NF-kappaB expression in Hodgkin's disease: Inhibition of constitutively expressed NF-kappaB results in spontaneous caspase-independent apoptosis in Hodgkin and Reed-Sternberg cells
52. Apoptosis and radiosensitization of Hodgkin cells by proteasome inhibition
53. Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids
54. Cancer Statistics, 2000
55. Myeloma cell adhesion to fibronectin activates NF-κB and induces the expression of genes contributing to cell adhesion-mediated drug resistance
56. The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma
57. The proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression
58. Proteasome inhibition: A novel mechanism to combat asthma
59. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma
60. Proteasome inhibitor PS-341 is effective as an anti-angiogenic agent in the treatment of human pancreatic carcinoma via the inhibition of NF-kB and subsequent inhibition of vascular endothelial growth factor production
61. The proteasome is involved in angiogenesis
62. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning
63. Constitutive nuclear factor-kB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells
64. Antitumor activity of the proteasome inhibitor PS-341 in mantle cell lymphoma B cells
65. Proteasome inhibition measurements: Clinical application
66. Clinical development of a proteasome inhibitor, PS-341, for the treatment of cancer
67. Phase II study of the proteasome inhibitor PS-341 in multiple myeloma (MM) patients (pts) with relapsed/refractory disease
68. Phase II study of PS-341, a novel proteasome inhibitor, alone or in combination with dexamethasone in patients with multiple myeloma who have relapsed following front-line therapy and are refractory to their most recent therapy